Table 4.

Multivariable association of an episode of AKI and change (fold increase) in level of urine protein-to-creatinine ratio using an AKI versus matched non-AKI episode modeling approach (i.e., comparing only a single pair of pre- and poststudy visits urine protein-to-creatinine ratios) overall and analyses that exclude receipt of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker or systolic BP level

ComparisonsFull Model (Shown in Supplemental Table 1)Model Excluding Receipt of ACE-I/ARBModel Excluding Systolic BP Level
Relative Risk (95% CI)P ValueRelative Risk (95% CI)P ValueRelative Risk (95% CI)P Value
AKI between study visits (versus no AKI)1.11 (1.02 to 1.21)0.021.11 (1.02 to 1.21)0.021.08 (0.99 to 1.18)0.09
  • ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; 95% CI, 95% confidence interval.